WO2023143486A9 - Sel, forme cristalline, solvate et hydrate de composé - Google Patents
Sel, forme cristalline, solvate et hydrate de composé Download PDFInfo
- Publication number
- WO2023143486A9 WO2023143486A9 PCT/CN2023/073504 CN2023073504W WO2023143486A9 WO 2023143486 A9 WO2023143486 A9 WO 2023143486A9 CN 2023073504 W CN2023073504 W CN 2023073504W WO 2023143486 A9 WO2023143486 A9 WO 2023143486A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solvate
- hydrate
- salt
- crystalline form
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Secondary Cells (AREA)
- Battery Electrode And Active Subsutance (AREA)
Abstract
La présente invention concerne un sel, une forme cristalline, un solvate ou un hydrate de 6-(éthylamino)-4-(6-(6-((6-méthoxypyridin-3-yl) méthyl)-3,6-diazabicyclo[3.1.1]heptane-3-yl) pyrazolo[1,5-a]pyridine-3-carbonitrile, ainsi qu'une composition pharmaceutique contenant le sel, la forme cristalline, le solvate ou l'hydrate, et concerne également une utilisation du sel, de la forme cristalline, du solvate ou de l'hydrate dans la préparation d'un médicament pour le traitement de maladies associées à RET.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210111424.X | 2022-01-19 | ||
| CN202210111424 | 2022-01-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2023143486A1 WO2023143486A1 (fr) | 2023-08-03 |
| WO2023143486A9 true WO2023143486A9 (fr) | 2023-09-21 |
Family
ID=87470637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2023/073504 WO2023143486A1 (fr) | 2022-01-29 | 2023-01-28 | Sel, forme cristalline, solvate et hydrate de composé |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2023143486A1 (fr) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220259201A1 (en) * | 2019-05-14 | 2022-08-18 | Shanghai Hansoh Biomedical Co., Ltd. | Inhibitor containing bicyclic derivative, preparation method therefor and use thereof |
| WO2021088911A1 (fr) * | 2019-11-08 | 2021-05-14 | 杭州邦顺制药有限公司 | Dérivé de 3,6-diazabicyclo[3.1.1]heptane utilisé en tant qu'inhibiteur de kinase ret |
| CN112939967A (zh) * | 2019-12-11 | 2021-06-11 | 深圳晶泰科技有限公司 | 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用 |
| CN113880865A (zh) * | 2020-07-01 | 2022-01-04 | 上海艾力斯医药科技股份有限公司 | 吡唑[1,5-a]吡啶类化合物及其制备方法与应用 |
| CN114621256A (zh) * | 2020-12-11 | 2022-06-14 | 深圳众格生物科技有限公司 | 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用 |
-
2023
- 2023-01-28 WO PCT/CN2023/073504 patent/WO2023143486A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023143486A1 (fr) | 2023-08-03 |
| TW202340201A (zh) | 2023-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI649326B (zh) | 苯并氧氮呯噁唑啶酮化合物及其製備方法 | |
| IL182893A0 (en) | PYRAZOLO-[1,5-a] PYRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | |
| US11434233B2 (en) | Heterocyclic inhibitors of ATR kinase | |
| WO2007120752A3 (fr) | Tétrahydroptéridines servant d'inhibiteurs de proteines kinases | |
| NZ766835A (en) | Pharmaceutical compounds | |
| MY146474A (en) | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors | |
| PL373414A1 (en) | 8-methoxy-(1,2,4)triazolo(1,5-a)pyridine derivatives and their use as adenosine receptor ligands | |
| AU6422399A (en) | 6-substituted pyrazolo(3,4-d)pyrimidin-4-ones useful as cyclin dependent kinase inhibitors | |
| SG156521A1 (en) | 4-amino-6-phenyl-pyrrolo[2,3-d] pyrimidine derivatives | |
| WO2007040438A3 (fr) | Derives d'imidazo(4,5-b) pyridine utilises comme inhibiteurs de la glycogene synthase kinase 3 pour le traitement de la demence et de troubles neurodegeneratifs | |
| WO2003070236A3 (fr) | Derives de pyrazole tricyclique, procedes de leur preparation et leur utilisation en tant qu'agents anti-tumoraux | |
| TNSN06226A1 (en) | Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases | |
| CN102753548A (zh) | 作为syk抑制剂的稠合的杂芳族吡咯烷酮 | |
| SI1427708T1 (sl) | Derivati amino-ftalazinona kot zaviralci kinaze, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo | |
| WO2014130856A2 (fr) | Traitement de troubles associés au squelette | |
| MY135902A (en) | SUBSTITUTED HEXAHYDROPYRAZINO [1, 2-a] PYRIMIDINE-4, 7-DIONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | |
| WO2008070313A3 (fr) | Dérivés de 3-(dihydro-1h-pyrazolo [4,3-d]pyrimidin-5-yl)-4-propoxybenzènesulfonamide et procédés d'utilisation | |
| IL158667A0 (en) | Imidazo [1,2-a] pyridine derivatives for the prophylaxis and treatment of herpes viral infections | |
| CN105461694A (zh) | 取代的杂芳基化合物及其组合物和用途 | |
| MX2010006748A (es) | Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2. | |
| JP7341156B2 (ja) | Ａｔｒキナーゼの複素環式阻害剤 | |
| EA200600209A1 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[3,4-c]ПИРАЗОЛА, ОБЛАДАЮЩИЕ АКТИВНОСТЬЮ КАК ИНГИБИТОРЫ КИНАЗЫ | |
| WO2006016067A3 (fr) | Derives de pyrido-pyrimidine, leur preparation, leur application dans le traitement du cancer | |
| WO2003063764A3 (fr) | Derives de pyrazolo[3,4-d]pyrimidin-4-ones substitues en position 6 utiles en tant qu'inhibiteurs de la kinase dependante des cyclines | |
| WO2023143486A9 (fr) | Sel, forme cristalline, solvate et hydrate de composé |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23746364 Country of ref document: EP Kind code of ref document: A1 |